Compulsory licensing threat in Europe requires vigilance from pharma patent owners
Reset password
Register to access two of our subscriber only articles per month.
Register
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe
Author | Life sciences reporter
[email protected]
@IAM_magazine US patent grants declined in 2020, but remain at historically high levels https://t.co/sM0WbWBiT4 https://t.co/Z9gLXQbRpr Read more
@IAM_magazine Smaller deals, younger rights, future standards: Oppo's patent buying strategy https://t.co/yJDCHFC0Gf https://t.co/vmQ4Jsp080 Read more
@IAM_magazine IV's new dealmaker gets off to a flier, tapping new licensing opportunities and the other key takeaways from the bi… https://t.co/08XqPRUi0N Read more
@IAM_magazine The new Brazilian biotech patent examination guidelines are a “missed opportunity” - but there is some good news fr… https://t.co/0xsWogw9VY Read more
